BRIEF published on 10/05/2026 at 13:17, 1 month 15 days ago ReproNovo Named Among "Fierce 15" Biotech Companies of 2026 Biotechnology Fertility Women's Health ReproNovo Fierce 15
PRESS RELEASE published on 10/05/2026 at 13:12, 1 month 15 days ago FIERCE BIOTECH NAMES REPRONOVO A “FIERCE 15” BIOTECH COMPANY OF 2026 ReproNovo named as one of 2026's Fierce 15 biotechnology companies by Fierce Biotech for innovative therapies targeting male and female infertility and women's health Innovation Biotechnology Fertility ReproNovo Fierce 15
BRIEF published on 07/06/2026 at 07:05, 4 months 15 days ago ReproNovo Begins EU Phase 2 Trial for Embryo Implantation Treatment ReproNovo RPN-002 Embryo Implantation NORDIC Trial Assisted Reproductive Technology
PRESS RELEASE published on 07/06/2026 at 07:00, 4 months 15 days ago ReproNovo Announces First Participant Dosed In EU Phase 2 Trial Of RPN-002 Embryo Implantation ReproNovo doses first participant in EU Phase 2 trial of RPN-002 for embryo implantation, aiming to increase IVF success rates with oxytocin receptor antagonist ReproNovo RPN-002 Embryo Implantation EU Phase 2 Trial IVF Success
BRIEF published on 03/20/2026 at 13:05, 8 months ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
PRESS RELEASE published on 03/20/2026 at 13:00, 8 months ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 1 year 1 month ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
PRESS RELEASE published on 09/30/2025 at 07:00, 1 year 1 month ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 1 year 4 months ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
PRESS RELEASE published on 07/01/2025 at 07:00, 1 year 4 months ago REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
Published on 11/20/2026 at 15:00, 17 hours 34 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 17 hours 44 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 18 hours 34 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 19 hours 4 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 19 hours 4 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 8 hours 48 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 10 hours 57 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 13 hours 7 minutes ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 13 hours 30 minutes ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 13 hours 59 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 14 hours 59 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 13 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing